Skip to content
Business

Kraig Biocraft Laboratories Ships Its First Commercial Spider Silk Yarn Order

Kraig Biocraft Laboratories has shipped its first commercial order of spider silk yarn to an unnamed sports brand, but gave no volume or price and reported no revenue in the first half of 2026.

Kraig Labs staff in lab coats packing items into wooden Kraig Labs crates in a laboratory, published with the 29 September 2026 yarn order release
Photo: Kraig Biocraft Laboratories

Kraig Biocraft Laboratories says it has shipped its first commercial order of spider silk yarn, made for an unnamed global sports brand. The company did not disclose the volume, the price or the customer, and it reported no revenue in the first half of 2026.

A first commercial order

Kraig Biocraft Laboratories, a Michigan company quoted on the OTCQB under the ticker KBLB, announced on 29 September that it had shipped custom spider silk yarn to fill a purchase commitment from what it called a globally recognised performance sports brand.

The yarn is meant to be developed into a new performance textile. The order is part of a confidential pilot development programme aimed at the innovation end of athletic apparel, and the yarn was processed to the customer's specifications.

Kraig makes its material with genetically engineered silkworms that carry key spider silk proteins, so the worms spin a recombinant spider silk rather than ordinary silk.

Kraig Biocraft Laboratories: share price, chart and news

Four Kraig Labs staff in lab coats beside wooden Kraig Labs shipping crates in a laboratory, published with the 29 September 2026 yarn order release.
Four Kraig Labs staff in lab coats beside wooden Kraig Labs shipping crates in a laboratory, published with the 29 September 2026 yarn order release. Photo: Kraig Biocraft Laboratories

What the company did and did not say

The release leaves out the numbers investors would normally use to judge an order. There is no quantity, no price and no customer name.

Founder and chief executive Kim Thompson said the volume was small on purpose. "This is a precision application, not a bulk order," she said, adding that the company intends this to be the first of many.

Kraig argued that elite performance apparel is a proving ground for its silk: a successful product would show that recombinant spider silk can meet the technical demands of top-level sport and could draw in other apparel brands. That is the company's view, and it published no test data on the yarn's performance.

The release cited a Textile Exchange report, published on 22 September, showing global fibre production reached a record 139 million tonnes in 2025, with polyester accounting for 59% of the total. Kraig said new fibres must offer different properties and prove they can be made consistently to win a place in that market.

The financial position behind the order

Kraig Labs at 30 June 2026

  • $0 revenue in the first six months of 2026
  • $1.85m net loss for the six months
  • $3.39m cash and cash equivalents

Kraig's most recent quarterly filing with the US Securities and Exchange Commission, for the period to 30 June, shows a company still in development. It had no revenue in the first half and a net loss of $1,852,255, up from $1,326,166 a year earlier.

Cash stood at $3,391,646 at 30 June, up from $1,790,236 at the end of 2025. Most of the increase came from selling shares: in the first half Kraig sold 25,364,093 shares for $2,772,547 under a standby equity purchase agreement that allows it to sell up to $10m of stock to an investor.

The balance sheet is weak. Total liabilities of $11.0m exceeded total assets of $4.3m, leaving a stockholders' deficit of $6.75m, and the company reported a working capital deficiency of $7.33m. Much of the liabilities are amounts owed to a related party. The filing says these conditions raise substantial doubt about Kraig's ability to continue as a going concern.

What it means for investors

A first shipment to a paying customer is a step a development company needs to take. But a small, undisclosed order does not yet show that Kraig can sell spider silk at a scale that covers its costs.

The company had 1,115,334,070 shares outstanding on 13 August. Continued share sales under the equity agreement would add to that count and dilute existing holders, while the going concern warning shows the business depends on raising money.

Investors will be looking for the size and value of any follow-on orders, whether the sports brand turns the yarn into a product, and whether sales start to appear in the company's revenue line.

Sources

Related stories

Investing

Kraig Biocraft Laboratories Profile: Spider Silk From Silkworms, Still Before Revenue

Kraig Biocraft Laboratories breeds silkworms that spin spider silk and farms them in Vietnam. It has begun shipping yarn but reported no revenue in the first half and carries a…

Business

Viking Therapeutics Raises $575m After Its Obesity Drug Holds Weight Off on Monthly Doses

Viking Therapeutics sold $316m of shares at $35 and $259m of 2% convertible notes, priced a day after data showing patients kept most of their weight loss on monthly or…

Business

Telix Agrees to Buy Munich Isotope Maker ITM for Up to $2.35bn

Australia's Telix Pharmaceuticals agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront, mostly in shares, plus up to $700 million tied to its lead cancer drug.

Business

Banyan Gold Closes a C$54.3m Share Sale as Franco-Nevada Buys 10 Million Shares

Banyan Gold has closed a C$54.3m placement at C$2.00 a share, with Franco-Nevada taking 10 million shares, to fund drilling, engineering and permitting at its AurMac project in…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…